Alpha 2.0
Login Register
» Articles » PMID: 3159336

Activities of Pefloxacin and Ciprofloxacin in Experimentally Induced Pseudomonas Pneumonia in Neutropenic Guinea Pigs

Overview
Journal Antimicrob Agents Chemother
Publisher American Society for Microbiology
Specialty Pharmacology
Date 1985 Apr 1
PMID 3159336
Citations 18
Authors
F M Gordin
C J Hackbarth
K G SCOTT
M A Sande
Affiliations
Soon will be listed here.
Abstract

Pefloxacin and ciprofloxacin are two new quinoline carboxylic acid derivatives that have activity in vitro against a wide range of gram-negative bacteria, including Pseudomonas aeruginosa. Using a well-standardized model of Pseudomonas pneumonia in neutropenic guinea pigs, we tested the efficacy in vivo of these new agents. Both were highly effective in increasing survival and decreasing bacterial counts in the lungs of surviving animals. Pefloxacin and ciprofloxacin were significantly better (P less than 0.05) than aminoglycosides or beta-lactams tested in prior studies with this model, and they were as effective as combination therapy with aminoglycosides and beta-lactams. Resistance to either ciprofloxacin or pefloxacin did not emerge during the study period. Further studies with these drugs in the therapy of Pseudomonas sp. infections are warranted.

Citing Articles

Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.

Goulenok T, Fantin B Clin Pharmacokinet. 2013; 52(10):869-83.

PMID: 23807657 DOI: 10.1007/s40262-013-0086-1.

Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats.

ten Kate M, Guo L, Working P, Mouton J Antimicrob Agents Chemother. 2001; 45(5):1487-92.

PMID: 11302815 PMC: 90493. DOI: 10.1128/AAC.45.5.1487-1492.2001.

Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance.

Dalhoff A Infection. 1994; 22 Suppl 2:S111-21.

PMID: 7927829 DOI: 10.1007/BF01793575.

Should Pseudomonas aeruginosa isolates resistant to one of the fluorinated quinolones be tested for the others? Studies with an experimental model of pneumonia.

Chidiac C, Roussel-Delvallez M, Guery B, Beaucaire G Antimicrob Agents Chemother. 1995; 39(3):677-9.

PMID: 7793872 PMC: 162604. DOI: 10.1128/AAC.39.3.677.

The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.

Hyatt J, McKinnon P, Zimmer G, Schentag J Clin Pharmacokinet. 1995; 28(2):143-60.

PMID: 7736689 DOI: 10.2165/00003088-199528020-00005.

References
1.
Thibault M, Koumare B, Soussy C, Duval J . [Structure-activity relationships in the quinolone group: antibacterial activity of two new compounds (author's transl)]. Ann Microbiol (Paris). 1981; 132(3):267-81. View
2.
Thabaut A, Durosoir J . [Comparison of the antimicrobial activity of pefloxacin (1589 RB), nalidixic acid and flumequin (author's transl)]. Pathol Biol (Paris). 1982; 30(6):394-7. View
3.
Wise R, Andrews J, Edwards L . In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother. 1983; 23(4):559-64. PMC: 184701. DOI: 10.1128/AAC.23.4.559. View
4.
Fass R . In vitro activity of ciprofloxacin (Bay o 9867). Antimicrob Agents Chemother. 1983; 24(4):568-74. PMC: 185375. DOI: 10.1128/AAC.24.4.568. View
5.
Crump B, Wise R, Dent J . Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother. 1983; 24(5):784-6. PMC: 185942. DOI: 10.1128/AAC.24.5.784. View